---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-11-20T06:49:17.063889'
end_time: '2025-11-20T06:58:54.039566'
duration_seconds: 576.98
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 88
---

## Question

Here is a pathway that describes how a drug might affect a disease:

**Pathway:** SmallMolecule: Icosapent | treats_or_applied_or_studied_to_treat | Disease: head and neck squamous cell carcinoma | treats_or_applied_or_studied_to_treat | SmallMolecule: Erlotinib | treats_or_applied_or_studied_to_treat | Disease: atherosclerosis

**Drug:** Icosapent
**Disease:** atherosclerosis

What is the biological plausibility of this drug-disease relationship?

Score on a scale of:
- 1 = Totally implausible (doesn't make sense biologically and no support in literature)
- 2 = Seems implausible (no support in literature)
- 3 = Seems plausible (no support in literature)
- 4 = Very plausible (some support in literature)
- 5 = Totally plausible (mechanism already described)

Consider:
- Has this exact mechanism been described in the literature?
- Do all, most, or some of the steps in the pathway have support in the literature?
- Do all, most, or some of the steps seem biologically plausible even without direct literature support?


## Output

# Icosapent and Atherosclerosis: Evaluating Biological Plausibility

## Introduction and Key Concepts  
**Icosapent (Drug):** Icosapent ethyl (brand name Vascepa) is a highly purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid. It is FDA-approved to reduce the risk of cardiovascular events in high-risk patients with elevated triglycerides, based on evidence that high-dose EPA can improve lipid profiles and exert anti-inflammatory effects. Mechanistically, omega-3 PUFAs like EPA help shift lipoproteins to a less atherogenic profile and incorporate into cell membranes, which promotes plaque stability and reduces vascular inflammation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this)). These properties underlie Icosapent’s cardioprotective effects. For example, the REDUCE-IT trial (2018) demonstrated that adding 4 g/day of Icosapent to statin therapy reduced the risk of major cardiovascular events by 25% (first occurrences) and total events by 32% ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients)). This large outcome trial established Icosapent’s **real-world application** in atherosclerotic cardiovascular disease prevention. Recent imaging studies further support its benefits: the 2020 EVAPORATE trial showed that Icosapent plus statins significantly **slowed and even reversed** the progression of coronary plaque. Over 18 months, low-attenuation coronary plaque volume *decreased by 17%* in the Icosapent group, while it more than doubled (+109%) in the placebo group ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant)). Other plaque components (fibrous and fibrofatty tissue) regressed under Icosapent but progressed with placebo ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=plaque%20volume%20more%20than%20doubled,053)). These data provide mechanistic evidence that Icosapent directly attenuates atherosclerosis progression, complementing its lipid-lowering and anti-inflammatory actions.

**Atherosclerosis (Disease):** Atherosclerosis is a chronic inflammatory disease of medium and large arteries characterized by lipid deposition, immune-cell infiltration, and fibrous plaque formation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=Coronary%20atherosclerosis%20is%20the%20principal,7%7D.%20Among%20these%20changes%2C%20chronic)). It underlies coronary artery disease, peripheral arterial disease, and stroke, making it a leading cause of morbidity and mortality worldwide. Current understanding emphasizes that **inflammation and oxidative stress** drive plaque development – LDL cholesterol accumulates and oxidizes in the arterial wall, triggering an immune response. Macrophages take up oxidized LDL to form foam cells, while T-lymphocytes and vascular smooth muscle cells proliferate and secrete cytokines, propagating chronic inflammation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=development,laden%20foam%20cells%5E%7B11%7D.%20Studies)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=Atherosclerosis%20is%20a%20progressive%20disease,increased%20EGFR%20phosphorylation%20and%20activity)). These processes cause plaque growth and instability. Notably, emerging research draws parallels between atherosclerosis and cancer biology. Cells in plaques exhibit hallmarks resembling tumors (e.g. sustained proliferation, angiogenesis, immune evasion) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=and%20maladaptive%20neovascularization,work%20should%20focus%20on%20biomarker)). This conceptual overlap has prompted interest in **repurposing oncology drugs** for atherosclerosis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=proliferative%20signaling%2C%20evasion%20of%20immune,target%20effects%20while%20enhancing%20efficacy)) – for instance, therapies targeting growth factor signaling or inflammation in cancer might modulate similar pathways in vascular disease.

Against this backdrop, the query proposes a multi-step **pathway** linking Icosapent to atherosclerosis via an intermediate disease (head and neck squamous cell carcinoma, HNSCC) and another drug (Erlotinib). The hypothesized chain is: 

- **Step 1:** *Icosapent* –studied as a treatment→ *Head and Neck Squamous Cell Carcinoma (HNSCC)*  
- **Step 2:** *HNSCC* –treated by→ *Erlotinib* (an EGFR inhibitor)  
- **Step 3:** *Erlotinib* –studied as treatment→ *Atherosclerosis*  

This implies Icosapent might affect atherosclerosis through mechanisms related to cancer treatment or shared pathways (particularly involving the EGFR signaling axis). We will examine each step for support in the literature and biological plausibility, then assess how convincingly they establish an Icosapent–atherosclerosis relationship.

## Step 1: Icosapent in Head and Neck Squamous Cell Carcinoma (HNSCC)  
**Rationale and Current Understanding:** HNSCC is an aggressive cancer often accompanied by systemic inflammation and cachexia (weight loss and muscle wasting). Omega-3 fatty acids like EPA have been investigated in oncology primarily for their anti-inflammatory and anti-cachectic benefits, rather than direct tumoricidal effects. Preclinical studies have suggested that omega-3s can modulate inflammatory pathways and possibly tumor cell metabolism, which provided a rationale to test EPA in cancer patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L107%20cancer,3%20class)). In particular, EPA supplementation might help maintain body weight, improve nutritional status, and even enhance treatment tolerance or quality of life in cancer patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L119%20supplementation%20could,3%20fatty)). These potential benefits are **biologically plausible** given EPA’s known role in dampening inflammatory cytokines and its incorporation into cell membranes, which can alter signaling pathways. Some reviews have hypothesized that EPA/DHA could improve clinical outcomes or immune function in cancer, though evidence has been mixed ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=weight%20loss%2C%20body%20composition%20and,DHA)).

**Recent Developments:** There is **some support in the literature** for Icosapent (EPA) being studied in HNSCC patients, mainly as a nutritional intervention. For example, a **2025 double-blind placebo-controlled trial** examined the effect of EPA supplementation on patients with locally advanced HNSCC undergoing curative treatment ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment)). The goal was to see if Icosapent could preserve body weight, body mass index (BMI), and skeletal muscle during therapy, thereby counteracting cachexia. This study (Arribas *et al.*, *Nutrition Journal*, 2025) found that while EPA was safe and feasible, it did **not show a statistically significant benefit** on weight or muscle preservation compared to placebo ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further)). In the per-protocol analysis, the EPA-supplemented group lost about 3.8 kg body weight versus 7.7 kg in the placebo group, but the difference was not significant (p > 0.05) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=statistically%20significant%20differences%20between%20groups,No%20differences%20were)). In other words, patients on Icosapent tended to lose less weight, but variability was high and results were inconclusive. This aligns with earlier mixed evidence – a systematic review noted some favorable effects of omega-3 on cancer-related weight loss, but overall findings have been inconsistent ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L107%20cancer,3%20class)).

**Interpretation:** From a *mechanistic* perspective, it is biologically plausible that EPA could exert anti-cancer or supportive effects (through anti-inflammatory action or improving nutrition in HNSCC patients). Omega-3 fatty acids may reduce production of pro-inflammatory prostaglandins and cytokines, potentially slowing cancer cachexia or even tumor-promoting inflammation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L107%20cancer,3%20class)). However, **no robust literature exists showing Icosapent can directly shrink head and neck tumors or serve as a primary cancer therapy.** The studies so far treat EPA as an *adjunct* for nutritional support. The pathway step stating “Icosapent treats or is applied to treat HNSCC” has *some* support in that trials have *applied* Icosapent to HNSCC patients, but this was not for curing the cancer itself. Thus, Step 1 is **biologically plausible** (EPA can impact cancer patient outcomes via inflammation/cachexia pathways) but only **partially supported** by literature, and the support shows limited or no efficacy in practice ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further)). There is no evidence that an EPA-based mechanism is a known effective *treatment* for HNSCC tumors.

## Step 2: Erlotinib and EGFR Targeting in HNSCC  
**Current Understanding:** Epidermal Growth Factor Receptor (EGFR) is a well-established oncogenic driver in many head and neck squamous cell carcinomas. Approximately 80–90% of HNSCC tumors overexpress EGFR, and this overexpression correlates with aggressive disease and poor prognosis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6)). Consequently, EGFR has been a major therapeutic target in HNSCC. Monoclonal antibodies against EGFR (like cetuximab) are FDA-approved for HNSCC, and small-molecule EGFR tyrosine kinase inhibitors (TKIs) have also been extensively studied. **Erlotinib** is one such TKI that selectively inhibits EGFR’s intracellular kinase domain, blocking downstream signaling that drives cell proliferation and survival ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=members%20of%20the%20RTK%20family,EGFR%20and%20prevent%20activation%20of)). 

**Literature Support:** The relationship “HNSCC is treated by Erlotinib” is **strongly supported by clinical research**. Multiple trials in the late 2000s and 2010s evaluated erlotinib in HNSCC, both alone and in combination regimens. For instance, a Phase III trial in 2006 (SiSi et al.) showed that adding cetuximab (an EGFR inhibitor) to radiation improved survival, establishing EGFR inhibition as beneficial in HNSCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=options%20and%20poor%20overall%20survival,pembrolizumab%20and%20nivolumab%20have%20demonstrated)). Erlotinib, as an oral EGFR inhibitor, was tested in recurrent/metastatic HNSCC: a multicenter Phase II study reported a modest **4.3% objective response rate** with erlotinib monotherapy, median progression-free survival ~10 weeks, and median overall survival ~6 months ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L473%20gefitinib%20to,72)). This modest activity indicated that erlotinib alone has limited efficacy in unselected HNSCC patients. However, other studies combining erlotinib with chemotherapy or radiation showed more encouraging results. For example, a randomized Phase II trial found that adding erlotinib to platinum–docetaxel chemotherapy improved progression-free survival in recurrent/metastatic HNSCC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=gefitinib%20to%20docetaxel%20did%20not,72)). Erlotinib has also been combined with radiotherapy in locally advanced cases and tested as an adjuvant therapy in clinical trials ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L321%20NCT00304278%20,Change%20in%20apoptotic%20index)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=single%20targeted%20agents%20such%20as,However%2C%20the%20study%20had)). While erlotinib never became a standard first-line HNSCC treatment (due to relatively small benefits and the success of immune checkpoint inhibitors in this disease), it is **biologically very plausible** and documented that erlotinib can treat HNSCC by targeting EGFR. Indeed, EGFR inhibition remains a valid approach: cetuximab is an approved therapy in HNSCC, and second-generation EGFR TKIs (afatinib, dacomitinib) have also shown activity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=members%20of%20the%20RTK%20family,EGFR%20and%20prevent%20activation%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=pathways%20compared%20to%20cetuximab%20and,in%20patients%20with%20progressive%20RM)). Thus, Step 2 of the pathway has **clear support in literature** – EGFR is a critical target in HNSCC and erlotinib has been **studied in numerous trials as a treatment for HNSCC**, even if outcomes were mixed. This step is **“Very plausible”** and grounded in current oncologic practice.

## Step 3: Erlotinib (EGFR Inhibition) in Atherosclerosis  
**Biological Rationale:** Given EGFR’s role in cell growth and inflammation, researchers have explored whether EGFR signaling also contributes to atherosclerotic plaque development. It turns out that vascular cells and leukocytes can express EGFR, and this pathway may promote the pathological processes of atherosclerosis. Recent studies indicate that EGFR is **upregulated and activated in atherosclerotic lesions**, where it can exacerbate inflammation, oxidative stress, and smooth muscle cell (SMC) proliferation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=mechanisms%20are%20complex%20and%20not,role%20on%20the%20pathogenesis%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=apolipoprotein%20E%20null%20mice,the%20prevention%20of%20atherosclerosis%20development)). For instance, Wang *et al.* (2017) found increased EGFR phosphorylation in the aortas of hyperlipidemic mice with plaques. Activation of EGFR in the vessel wall may occur via inflammatory mediators (e.g. EGFR transactivation by Toll-like receptor signaling) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=stress%2C%20macrophage%20infiltration%2C%20induction%20of,the%20prevention%20of%20atherosclerosis%20development)). These insights raise the question: Could blocking EGFR signaling slow down atherosclerosis? 

**Evidence and Recent Developments:** Preclinical research strongly suggests **yes**. In 2017–2018, independent groups demonstrated that pharmacologically inhibiting EGFR can ameliorate atherosclerosis in animal models. A *Science Reports* 2017 study showed that an EGFR blocker reduced plaque burden in ApoE⁻/⁻ mice fed a high-fat diet, correlating with lower oxidative stress and fewer inflammatory cells in lesions ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=mechanisms%20are%20complex%20and%20not,role%20on%20the%20pathogenesis%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=stress%2C%20macrophage%20infiltration%2C%20induction%20of,the%20prevention%20of%20atherosclerosis%20development)). More directly relevant, a 2018 study published in *JACC* (American College of Cardiology) examined the effect of **erlotinib** on atherosclerosis in LDLR⁻/⁻ mice. The findings were striking: **erlotinib treatment protected against atherosclerotic lesion development and progression** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice)). Erlotinib caused CD4⁺ T-cells to become “anergic” (unresponsive) and significantly **reduced T-cell infiltration** into plaques ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,2%20production)). Since T-lymphocytes drive inflammation in plaques, their suppression led to smaller lesions. In mice given erlotinib, as well as in genetically engineered mice lacking EGFR in T-cells, atherosclerotic plaques were about **50% smaller** than in controls after several months of high-fat diet ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=production,fat%20diet)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo)). Importantly, markers of inflammation (like interferon-γ and IL-6 from T-cells) were reduced, linking EGFR blockade to an anti-inflammatory effect in arterial walls ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,EGFR%20inhibition%20reduced%20T%20cell)). 

These preclinical results make a compelling case that **EGFR is involved in atherogenesis and that EGFR inhibitors (like erlotinib)** can attenuate plaque formation. Leading cardiovascular immunologists (e.g. Dr. Peter Libby) have noted that targeting immune and inflammatory pathways is a promising avenue for treating atherosclerosis ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Comment%20in)). EGFR inhibition represents one such novel strategy ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Conclusions%3A%20EGFR%20blockade%20induced%20T,novel%20strategy%20to%20combat%20atherosclerosis)). As of 2023, this concept remains largely at the experimental stage – there have not yet been clinical trials of erlotinib for atherosclerosis in humans, mainly due to concerns about toxicity and off-target effects for a chronic prevention setting ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=interest%20in%20the%20potential%20repurposing,target%20effects%20while%20enhancing%20efficacy)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=translation%20and%20integration%20of%20oncologic,target%20effects%20while%20enhancing%20efficacy)). However, the consistency of the animal data makes Step 3 **biologically very plausible**. It is **supported in literature** that blocking EGFR activity (via erlotinib or genetic deletion) dampens atherosclerotic plaque growth in vivo ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo)). Therefore, the link “Erlotinib treats or is studied to treat atherosclerosis” gets a plausibility score near the high end. It’s worth noting this is a cutting-edge idea: a 2025 review on repurposing cancer drugs for heart disease highlights EGFR inhibitors as potential anti-atherosclerotic agents, given the shared proliferation and angiogenesis pathways in cancer and plaques ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=and%20maladaptive%20neovascularization,work%20should%20focus%20on%20biomarker)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=proliferative%20signaling%2C%20evasion%20of%20immune,target%20effects%20while%20enhancing%20efficacy)).

## Direct Relationship: Icosapent and Atherosclerosis  
While the above steps establish a theoretical bridge between Icosapent and atherosclerosis (through a common cancer link and EGFR pathway), it’s also crucial to examine **direct evidence** linking Icosapent to atherosclerosis. In practice, Icosapent is already used for cardiovascular disease prevention, as discussed earlier. Beyond lowering triglycerides, multiple lines of research support a **biologically plausible mechanism** for Icosapent in mitigating atherosclerosis:

- **Clinical Outcome Evidence:** The **REDUCE-IT trial (NEJM 2019)** enrolled over 8,000 patients with high cardiovascular risk (many with established atherosclerotic disease) and elevated triglycerides. Patients on Icosapent Ethyl 4 g/day had a **significantly lower incidence of ischemic events** (such as heart attack and stroke) than those on placebo ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients)). This 25% relative risk reduction directly suggests Icosapent can modify disease processes in atherosclerosis, not just risk factors. In 2023, guidelines (e.g. ACC/AHA) incorporated Icosapent for secondary prevention in appropriate patients, reflecting expert consensus on its benefit.

- **Imaging and Plaque Studies:** As noted, the **EVAPORATE trial (European Heart J. 2020)** provided mechanistic insight by using coronary CT angiography. It showed that over 18 months, patients on Icosapent had **regression of vulnerable plaque**. Specifically, low-attenuation (soft, lipid-rich) plaque volume regressed by 17%, whereas it **expanded dramatically in the placebo group** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant)). Icosapent also slowed progression of fibrous plaques and calcifications relative to placebo ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=plaque%20volume%20more%20than%20doubled,053)). An editorial noted that EVAPORATE offers “important mechanistic data” explaining how Icosapent may stabilize plaques, aligning with the event reduction in REDUCE-IT ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Conclusions)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Given%20the%20robust%20cardiovascular%20event,with%20presence%20of%20significant%20atherosclerosis)).

- **Anti-Inflammatory and Plaque Stabilization:** Research into **how** Icosapent works has identified multiple **plausible mechanisms**. EPA gets incorporated into membrane phospholipids of cells (including endothelial cells and macrophages), which can alter membrane microdomains and receptor signaling. It also gives rise to anti-inflammatory eicosanoids (resolvins, protectins) instead of pro-inflammatory arachidonic acid derivatives. Gupta *et al.* (J. Clin. Med. 2023) note that EPA’s membrane incorporation leads to reduced inflammatory responses and improved plaque stability ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this)). They highlight that imaging studies consistently illustrate EPA’s plaque-stabilizing effects, even though not all clinical trials of omega-3 have been positive ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=cellular%20membrane%2C%20leading%20to%20plaque,will%20provide%20better%20insight%20into)). (For instance, the STRENGTH trial in 2020, using an EPA/DHA mixture, showed no cardiovascular benefit, underscoring that **Icosapent’s effects may be unique to high-dose pure EPA**). Overall, Icosapent is thought to reduce macrophage accumulation and oxidative stress in lesions, lower adhesion molecule expression, and possibly improve endothelial function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this)). These actions correspond to known drivers of atherosclerosis (inflammation, oxidation, SMC proliferation), interestingly paralleling some effects seen with EGFR inhibition in plaques ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=apolipoprotein%20E%20null%20mice,the%20prevention%20of%20atherosclerosis%20development)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice)).

- **Expert Opinion:** Leading cardiologists have lauded Icosapent Ethyl as a major advance for residual cardiovascular risk reduction. In an editorial accompanying REDUCE-IT’s publication (2019), experts pointed out that these results “redefine the role” of omega-3 therapy, moving it from a mere supplement to an evidence-based medication. The enthusiasm is tempered by ongoing debates about mechanism – **the exact pathway by which Icosapent reduces events is still under investigation** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients)). Some hypothesize it’s more than just triglyceride lowering (which was modest ~18% in REDUCE-IT); rather, its **anti-inflammatory and plaque effects** play a large part ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=remains,treated%20patients)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Given%20the%20robust%20cardiovascular%20event,with%20presence%20of%20significant%20atherosclerosis)). The FDA approval in December 2019 and subsequent guideline endorsements reflect a consensus that the drug’s benefits are real. Current real-world implementations include prescribing Icosapent to high-risk patients (e.g. those with prior myocardial infarction or diabetes with multiple risk factors) who have controlled LDL cholesterol but elevated triglycerides, to further reduce atherosclerotic events. This has made Icosapent an important adjunct to statins in cardiovascular medicine.

In summary, independent of the cancer-drug pathway, the **Icosapent–atherosclerosis link is strongly supported by recent research**. There is direct clinical evidence of benefit and a growing understanding of mechanisms (anti-inflammatory, plaque stabilization), though researchers continue to explore exactly how EPA achieves its protective effects. This gives the Icosapent–atherosclerosis relationship a high degree of plausibility.

## Plausibility Assessment of the Proposed Pathway  
Bringing all the pieces together, we evaluate how **biologically plausible** it is that Icosapent (the drug) could have a therapeutic effect on atherosclerosis (the disease) via the pathway described. Key considerations include whether each step of the chain is supported by literature and whether the chain as a whole “makes sense” biologically:

- **Literature Support for Each Step:**  
  - *Step 1 (Icosapent → HNSCC):* *Some* support, but limited. Icosapent (EPA) has been **studied in HNSCC patients** as a nutritional supplement to counteract weight loss ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment)). This indicates a recognized potential benefit (anti-inflammatory, metabolic support) in the cancer setting. However, trials did not show a clear clinical improvement in outcomes like weight preservation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further)). Crucially, no evidence shows Icosapent can directly treat or shrink HNSCC tumors. So, this step has **partial plausibility** – biologically feasible and attempted in practice, but not an established or effective mechanism in oncology.  
  - *Step 2 (HNSCC → Erlotinib):* Strong support. EGFR inhibition (via erlotinib or similar drugs) is a **validated treatment strategy in HNSCC** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6)). Erlotinib itself has been through clinical trials in this cancer, confirming that it can target the disease (even if outcomes were modest) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L473%20gefitinib%20to,72)). This step is **fully plausible** – it reflects known biology (EGFR drives HNSCC, blocking EGFR can slow the cancer) and is backed by extensive literature and even real-world use (erlotinib is approved for other EGFR-driven cancers and was trialed in HNSCC).  
  - *Step 3 (Erlotinib → Atherosclerosis):* Moderate-to-strong support, largely preclinical. There is **clear scientific literature** showing EGFR inhibitors like erlotinib can reduce atherosclerosis in animal models ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo)). The mechanism (reducing immune cell activation and inflammation in plaques) is well rationalized and aligns with our understanding of atherosclerosis pathophysiology ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=apolipoprotein%20E%20null%20mice,the%20prevention%20of%20atherosclerosis%20development)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,2%20production)). While human data are lacking, the consistency of experimental results makes this step **very plausible biologically**. It is a current topic of research and represents a novel therapeutic concept (supported by 2017–2021 studies). We consider this step supported (some literature exists, though mostly in mice, not yet in patients).

- **Chain Coherence:** All three steps individually have a rationale, but do they connect to make Icosapent treat atherosclerosis? If we follow the chain: Icosapent might influence HNSCC (perhaps by reducing inflammatory milieu or cancer cachexia); HNSCC in turn is treatable by erlotinib (through EGFR); erlotinib can treat atherosclerosis (through immune modulation). The *implicit assumption* is that Icosapent’s effect on HNSCC somehow relates to erlotinib’s effect – for example, maybe Icosapent could modulate EGFR signaling or substitute for erlotinib in some way. In reality, **there is no direct mechanistic link between Icosapent’s action in HNSCC and EGFR inhibition.** Icosapent does not target EGFR; its benefits in HNSCC (if any) would likely come from systemic anti-inflammatory effects or improved nutrition, not from the specific EGFR pathway that erlotinib affects. Therefore, the pathway as a literal step-by-step mechanism is somewhat tenuous. The chain is more of a heuristic association (Icosapent was trialed in the same disease where erlotinib works, and erlotinib works in atherosclerosis) than a single causal route. 

However, looking beyond the exact chain, we see a **convergence of themes**: both Icosapent and erlotinib confer benefits by *attenuating inflammation and cellular proliferation*, albeit in different contexts. Icosapent reduces systemic inflammation and stabilizes plaques; erlotinib reduces immune activation and cell growth in plaques. They act on distinct molecular targets (fatty acid pathways vs. EGFR signaling), but the end result – reducing atherosclerotic processes – is similar. So, even if Icosapent doesn’t operate via EGFR, it achieves overlapping outcomes (lowered plaque inflammation) through alternative pathways. This makes the **drug-disease relationship (Icosapent→atherosclerosis) biologically very plausible**, even if the intermediary of HNSCC → erlotinib is an indirect and arguably unnecessary link. In fact, the direct evidence for Icosapent’s effect on atherosclerosis (discussed above) is stronger than any theoretical cancer-mediated mechanism.

- **Has the exact mechanism been described?** No – the *exact proposed mechanism (Icosapent treating atherosclerosis via an HNSCC/erlotinib pathway)* has not been described in literature. There is no publication that strings together this specific chain. It’s an inferred pathway, likely generated by connecting known relationships in a database. We do not have a paper saying “Icosapent cures atherosclerosis by treating head and neck cancer and thereby mimicking erlotinib.” Thus, on the criterion of *“mechanism already described”*, the answer is negative. 

- **Do most steps have support in literature?** Yes, **most steps are supported** to some extent. Step 2 and 3 are clearly supported by studies (clinical trials for step 2; animal studies for step 3). Step 1 has been at least the subject of a trial (supporting the idea was worth testing) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment)). So we can say **all steps have at least some literature backing**, though the strength varies (strong for Step 2; moderate for Step 3; weak for Step 1). 

- **Biological plausibility of steps without direct support:** Even where direct evidence is thin (Step 1), the concept isn’t biologically far-fetched – EPA’s anti-inflammatory effects could plausibly benefit cancer patients. There’s nothing “unnatural” in the steps that defies biology (e.g., we are not suggesting an unrelated drug suddenly cures an unrelated disease without mechanistic rationale). Each link fits known biology: Omega-3 affects inflammation, EGFR drives cancer, EGFR also influences vascular inflammation. This lends *overall plausibility* to the idea that Icosapent could impact atherosclerosis, since the chain touches logical biological processes.

## Conclusion and Plausibility Score  
Considering the above, the **drug-disease relationship between Icosapent and atherosclerosis is biologically plausible** and in fact supported by significant evidence *outside* the given pathway. **Icosapent has documented anti-atherosclerotic effects**, so the end relationship is likely real. The provided pathway via HNSCC and erlotinib, however, is an indirect and novel way to connect the two; it is not an established mechanism but rather a combination of separate facts. There is partial support for each step and a unifying theme of anti-inflammatory action. Crucially, no contradictions in biology are present (it “makes sense” that reducing inflammation and proliferation could help in both cancer and plaque contexts).

On a **plausibility scale from 1 to 5** (with 1 = totally implausible, 5 = mechanism already established in literature), I would rate the Icosapent–atherosclerosis link as **4 out of 5: “Very plausible.”** This rating is justified because: 

- There is **some direct support in literature** for the overall idea (Icosapent’s benefits in atherosclerosis have been shown in trials and plaque studies ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant))), even though the exact multi-step chain is not explicitly documented. 
- **Most steps are supported** by scientific studies (particularly EGFR’s role in both HNSCC and atherosclerosis is evidenced ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice))). 
- All steps appear **biologically sensible** even where direct evidence is lacking – none of the links defy known mechanisms or physiology. 
- The mechanism is not *fully* described as one continuous pathway in literature (preventing a score of 5), but enough pieces exist to reconstruct a credible mechanism. 

In summary, the idea that Icosapent could help treat or prevent atherosclerosis is **highly plausible**. It is supported by our current understanding of both the drug’s properties and the disease’s biology. The intermediate connections (via cancer and erlotinib) highlight interesting common pathways (inflammation, growth signals) but are not strictly necessary to justify the link. Given the evidence from 2018–2024 research, we confidently score this relationship a **4/5 (very plausible)** – there is literature-based support for much of it, and the core mechanism (anti-inflammatory, plaque-modulating effect of Icosapent) is already being leveraged in clinical practice.

**References:** (Publication dates and sources included in citations)  

- Arribas *et al*., *Nutrition Journal*, 2025 – EPA supplementation trial in head & neck cancer ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further)).  
- Patel & Saba, *Cancers (Basel)*, 2021 – EGFR in HNSCC review (EGFR overexpression ~90% of tumors) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6)).  
- Nabil *et al*., *Cancers (Basel)*, 2021 – EGFR inhibitors in HNSCC (erlotinib trials outcomes) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L473%20gefitinib%20to,72)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=gefitinib%20to%20docetaxel%20did%20not,72)).  
- Wang *et al*., *Sci Reports*, 2017 – EGFR inhibition reduces atherosclerosis in ApoE⁻/⁻ mice (decreased inflammation/ROS) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=mechanisms%20are%20complex%20and%20not,role%20on%20the%20pathogenesis%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=stress%2C%20macrophage%20infiltration%2C%20induction%20of,the%20prevention%20of%20atherosclerosis%20development)).  
- Gisterå *et al*., *JACC*, 2018 – Erlotinib induces T-cell anergy and halved plaque size in mice (immune modulation in atherosclerosis) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo)).  
- Budoff *et al*., *Eur Heart J.*, 2020 – EVAPORATE trial (Icosapent regresses coronary plaque over 18 months) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=plaque%20volume%20more%20than%20doubled,053)).  
- Bhatt *et al*., *NEJM*, 2019 – REDUCE-IT trial (Icosapent reduces cardiovascular events by 25–30%) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients)).  
- Gupta *et al*., *J Clin Med*, 2023 – Mechanistic review of Icosapent (EPA) in CVD (plaque stabilization, anti-inflammatory effects) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=cellular%20membrane%2C%20leading%20to%20plaque,will%20provide%20better%20insight%20into)).  
- Liu *et al*., *Biomedicines*, 2025 – Review on repurposing cancer drugs for atherosclerosis (notes shared hallmarks and EGFR as a target) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=and%20maladaptive%20neovascularization,work%20should%20focus%20on%20biomarker)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=proliferative%20signaling%2C%20evasion%20of%20immune,target%20effects%20while%20enhancing%20efficacy)).

## Citations

1. AnnotationURLCitation(end_index=795, start_index=656, title='The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this')
2. AnnotationURLCitation(end_index=1205, start_index=1064, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients')
3. AnnotationURLCitation(end_index=1811, start_index=1683, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant')
4. AnnotationURLCitation(end_index=2050, start_index=1923, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=plaque%20volume%20more%20than%20doubled,053')
5. AnnotationURLCitation(end_index=2599, start_index=2421, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=Coronary%20atherosclerosis%20is%20the%20principal,7%7D.%20Among%20these%20changes%2C%20chronic')
6. AnnotationURLCitation(end_index=3253, start_index=3115, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=development,laden%20foam%20cells%5E%7B11%7D.%20Studies')
7. AnnotationURLCitation(end_index=3438, start_index=3254, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=Atherosclerosis%20is%20a%20progressive%20disease,increased%20EGFR%20phosphorylation%20and%20activity')
8. AnnotationURLCitation(end_index=3856, start_index=3694, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=and%20maladaptive%20neovascularization,work%20should%20focus%20on%20biomarker')
9. AnnotationURLCitation(end_index=4143, start_index=3958, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=proliferative%20signaling%2C%20evasion%20of%20immune,target%20effects%20while%20enhancing%20efficacy')
10. AnnotationURLCitation(end_index=5806, start_index=5685, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L107%20cancer,3%20class')
11. AnnotationURLCitation(end_index=6117, start_index=5979, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L119%20supplementation%20could,3%20fatty')
12. AnnotationURLCitation(end_index=6582, start_index=6450, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=weight%20loss%2C%20body%20composition%20and,DHA')
13. AnnotationURLCitation(end_index=7059, start_index=6920, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment')
14. AnnotationURLCitation(end_index=7546, start_index=7423, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further')
15. AnnotationURLCitation(end_index=7890, start_index=7721, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=statistically%20significant%20differences%20between%20groups,No%20differences%20were')
16. AnnotationURLCitation(end_index=8330, start_index=8191, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment')
17. AnnotationURLCitation(end_index=8452, start_index=8331, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L107%20cancer,3%20class')
18. AnnotationURLCitation(end_index=8956, start_index=8835, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L107%20cancer,3%20class')
19. AnnotationURLCitation(end_index=9711, start_index=9588, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further')
20. AnnotationURLCitation(end_index=10266, start_index=10152, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6')
21. AnnotationURLCitation(end_index=10829, start_index=10673, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=members%20of%20the%20RTK%20family,EGFR%20and%20prevent%20activation%20of')
22. AnnotationURLCitation(end_index=11434, start_index=11255, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=options%20and%20poor%20overall%20survival,pembrolizumab%20and%20nivolumab%20have%20demonstrated')
23. AnnotationURLCitation(end_index=11827, start_index=11706, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L473%20gefitinib%20to,72')
24. AnnotationURLCitation(end_index=12333, start_index=12208, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=gefitinib%20to%20docetaxel%20did%20not,72')
25. AnnotationURLCitation(end_index=12615, start_index=12465, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L321%20NCT00304278%20,Change%20in%20apoptotic%20index')
26. AnnotationURLCitation(end_index=12769, start_index=12616, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=single%20targeted%20agents%20such%20as,However%2C%20the%20study%20had')
27. AnnotationURLCitation(end_index=13371, start_index=13215, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=members%20of%20the%20RTK%20family,EGFR%20and%20prevent%20activation%20of')
28. AnnotationURLCitation(end_index=13538, start_index=13372, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=pathways%20compared%20to%20cetuximab%20and,in%20patients%20with%20progressive%20RM')
29. AnnotationURLCitation(end_index=14565, start_index=14407, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=mechanisms%20are%20complex%20and%20not,role%20on%20the%20pathogenesis%20of')
30. AnnotationURLCitation(end_index=14736, start_index=14566, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=apolipoprotein%20E%20null%20mice,the%20prevention%20of%20atherosclerosis%20development')
31. AnnotationURLCitation(end_index=15191, start_index=14996, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=stress%2C%20macrophage%20infiltration%2C%20induction%20of,the%20prevention%20of%20atherosclerosis%20development')
32. AnnotationURLCitation(end_index=15863, start_index=15705, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=mechanisms%20are%20complex%20and%20not,role%20on%20the%20pathogenesis%20of')
33. AnnotationURLCitation(end_index=16059, start_index=15864, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=stress%2C%20macrophage%20infiltration%2C%20induction%20of,the%20prevention%20of%20atherosclerosis%20development')
34. AnnotationURLCitation(end_index=16453, start_index=16345, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice')
35. AnnotationURLCitation(end_index=16701, start_index=16583, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,2%20production')
36. AnnotationURLCitation(end_index=17094, start_index=16994, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=production,fat%20diet')
37. AnnotationURLCitation(end_index=17246, start_index=17095, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo')
38. AnnotationURLCitation(end_index=17520, start_index=17412, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice')
39. AnnotationURLCitation(end_index=17682, start_index=17521, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,EGFR%20inhibition%20reduced%20T%20cell')
40. AnnotationURLCitation(end_index=18113, start_index=18022, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Comment%20in')
41. AnnotationURLCitation(end_index=18340, start_index=18166, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Conclusions%3A%20EGFR%20blockade%20induced%20T,novel%20strategy%20to%20combat%20atherosclerosis')
42. AnnotationURLCitation(end_index=18767, start_index=18589, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=interest%20in%20the%20potential%20repurposing,target%20effects%20while%20enhancing%20efficacy')
43. AnnotationURLCitation(end_index=18949, start_index=18768, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=translation%20and%20integration%20of%20oncologic,target%20effects%20while%20enhancing%20efficacy')
44. AnnotationURLCitation(end_index=19293, start_index=19185, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice')
45. AnnotationURLCitation(end_index=19445, start_index=19294, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo')
46. AnnotationURLCitation(end_index=19987, start_index=19825, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=and%20maladaptive%20neovascularization,work%20should%20focus%20on%20biomarker')
47. AnnotationURLCitation(end_index=20173, start_index=19988, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=proliferative%20signaling%2C%20evasion%20of%20immune,target%20effects%20while%20enhancing%20efficacy')
48. AnnotationURLCitation(end_index=21206, start_index=21065, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients')
49. AnnotationURLCitation(end_index=22011, start_index=21883, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant')
50. AnnotationURLCitation(end_index=22232, start_index=22105, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=plaque%20volume%20more%20than%20doubled,053')
51. AnnotationURLCitation(end_index=22494, start_index=22399, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Conclusions')
52. AnnotationURLCitation(end_index=22677, start_index=22495, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Given%20the%20robust%20cardiovascular%20event,with%20presence%20of%20significant%20atherosclerosis')
53. AnnotationURLCitation(end_index=23404, start_index=23265, title='The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this')
54. AnnotationURLCitation(end_index=23738, start_index=23566, title='The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=cellular%20membrane%2C%20leading%20to%20plaque,will%20provide%20better%20insight%20into')
55. AnnotationURLCitation(end_index=24237, start_index=24098, title='The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this')
56. AnnotationURLCitation(end_index=24592, start_index=24422, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=apolipoprotein%20E%20null%20mice,the%20prevention%20of%20atherosclerosis%20development')
57. AnnotationURLCitation(end_index=24701, start_index=24593, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice')
58. AnnotationURLCitation(end_index=25335, start_index=25194, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients')
59. AnnotationURLCitation(end_index=25615, start_index=25505, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=remains,treated%20patients')
60. AnnotationURLCitation(end_index=25798, start_index=25616, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Given%20the%20robust%20cardiovascular%20event,with%20presence%20of%20significant%20atherosclerosis')
61. AnnotationURLCitation(end_index=27481, start_index=27342, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment')
62. AnnotationURLCitation(end_index=27809, start_index=27686, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further')
63. AnnotationURLCitation(end_index=28308, start_index=28194, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6')
64. AnnotationURLCitation(end_index=28570, start_index=28449, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L473%20gefitinib%20to,72')
65. AnnotationURLCitation(end_index=29157, start_index=29049, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice')
66. AnnotationURLCitation(end_index=29309, start_index=29158, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo')
67. AnnotationURLCitation(end_index=29647, start_index=29477, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=apolipoprotein%20E%20null%20mice,the%20prevention%20of%20atherosclerosis%20development')
68. AnnotationURLCitation(end_index=29766, start_index=29648, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,2%20production')
69. AnnotationURLCitation(end_index=33210, start_index=33071, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment')
70. AnnotationURLCitation(end_index=35335, start_index=35207, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant')
71. AnnotationURLCitation(end_index=35648, start_index=35534, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6')
72. AnnotationURLCitation(end_index=35757, start_index=35649, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice')
73. AnnotationURLCitation(end_index=37059, start_index=36920, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=Evidence%20on%20the%20benefits%20of,intent%20treatment')
74. AnnotationURLCitation(end_index=37183, start_index=37060, title='Nutritional impact of eicosapentaenoic acid supplementation (EPA) in patients with locally advanced head and neck cancer: a double-blind placebo-controlled randomized trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12465153/#:~:text=match%20at%20L67%20Our%20study,Further')
75. AnnotationURLCitation(end_index=37401, start_index=37287, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=overall%205,4%29%20%5B%209%2C6')
76. AnnotationURLCitation(end_index=37623, start_index=37502, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=match%20at%20L473%20gefitinib%20to,72')
77. AnnotationURLCitation(end_index=37749, start_index=37624, title='Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8306284/#:~:text=gefitinib%20to%20docetaxel%20did%20not,72')
78. AnnotationURLCitation(end_index=38035, start_index=37877, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=mechanisms%20are%20complex%20and%20not,role%20on%20the%20pathogenesis%20of')
79. AnnotationURLCitation(end_index=38231, start_index=38036, title='Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC5379239/#:~:text=stress%2C%20macrophage%20infiltration%2C%20induction%20of,the%20prevention%20of%20atherosclerosis%20development')
80. AnnotationURLCitation(end_index=38480, start_index=38372, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=Results%3A%20Mouse%20CD4,mice')
81. AnnotationURLCitation(end_index=38632, start_index=38481, title='Selective EGF-Receptor Inhibition in CD4+ T Cells Induces Anergy and Limits Atherosclerosis - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29325640/#:~:text=T%20cell%20proliferation%20and%20activation,in%20vitro%20and%20in%20vivo')
82. AnnotationURLCitation(end_index=38875, start_index=38747, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=was%20259,did%20not%20show%20a%20significant')
83. AnnotationURLCitation(end_index=39003, start_index=38876, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=plaque%20volume%20more%20than%20doubled,053')
84. AnnotationURLCitation(end_index=39249, start_index=39108, title='Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7654934/#:~:text=Despite%20the%20effects%20of%20statins,treated%20patients')
85. AnnotationURLCitation(end_index=39526, start_index=39387, title='The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=therapeutic%20option%20for%20patients%20with,In%20this')
86. AnnotationURLCitation(end_index=39699, start_index=39527, title='The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10253987/#:~:text=cellular%20membrane%2C%20leading%20to%20plaque,will%20provide%20better%20insight%20into')
87. AnnotationURLCitation(end_index=40005, start_index=39843, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=and%20maladaptive%20neovascularization,work%20should%20focus%20on%20biomarker')
88. AnnotationURLCitation(end_index=40191, start_index=40006, title='Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12467425/#:~:text=proliferative%20signaling%2C%20evasion%20of%20immune,target%20effects%20while%20enhancing%20efficacy')